Abstract: Methods and compositions for treating a complication associated with aneurysmal subarachnoid hemorrhage (SAH), the method comprising administering an effective amount of a nitric oxide precursor to a subject in need thereof. Methods and compositions for treating vasospasm, the method comprising administering an effective amount of a nitric oxide precursor to a subject in need thereof.
Type:
Grant
Filed:
April 17, 2018
Date of Patent:
December 10, 2019
Assignee:
Vanderbilt University
Inventors:
Marshall L. Summar, Frederick E. Barr, Reid Carleton Thompson
Abstract: The present disclosure is directed to antibodies binding to human respiratory syncytial virus F protein, including both neutralizing and non-neutralizing antibodies, and methods for use thereof.
Abstract: Systems and methods are described for determining an orientation and position of a capsule inserted into the body of a patient. A magnetic field is applied to an area of the patient where the capsule is located. Sensor data, including inertial data from an inertial sensor and magnetic field data indicative of the applied magnetic field as detected by at least one magnetic field sensor, is wirelessly received from the capsule. An orientation angle of the capsule is determined based at least in part on the inertial data. The magnetic field data is compared to known characteristics of the applied magnetic field and a location of the capsule is determined based on the comparison.
Type:
Grant
Filed:
January 17, 2014
Date of Patent:
November 26, 2019
Assignee:
Vanderbilt University
Inventors:
Christian Di Natali, Marco Beccani, Pietro Valdastri, Keith L. Obstein
Abstract: Described are positive allosteric modulators of the GLP-1 receptor, pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for diabetes mellitus type 2, obesity, depression, Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke, cognitive dysfunction, learning disability, and asthma in a subject.
Abstract: Provided are compositions for inhibiting a biological activity of an aldo-keto reductase family 1, member C3 (AKR1C3) polypeptide. In some embodiments, the compositions are indomethacin derivatives that are AKR1C3-specific inhibitors. Also provided are methods for producing disclosed indomethacin derivatives that substantially lack cyclooxygenase inhibitory activity but that have AKR1C3 inhibitory activity, methods for inhibiting AKR1C3 polypeptide biological activities, and methods for treating prostate tumors in subjects.
Type:
Application
Filed:
August 2, 2019
Publication date:
November 21, 2019
Applicants:
Vanderbilt University, The Trustees of the University of Pennsylvania
Inventors:
Lawrence J. Marnett, Andy J. Liedtke, Trevor M. Penning, Adegoke O. Adeniji, Michael C. Byrns
Abstract: The present disclosure is directed to human monoclonal IgE antibodies, and IgG antibodies engineered therefrom. Such engineered antibodies can be used to blunt pathologic IgE responses in subjects, such as in the treatment or prevention of allergies.
Abstract: A surgical grasper includes a first handle arm, a second handle arm pivotally coupled to the first handle arm, a tool body pivotally coupled to both the first handle arm and the second handle arm, a first jaw member pivotally coupled to the tool body, a second jaw member pivotally coupled to the tool body, a first tension element coupled to both the first handle arm and to the first jaw member, a second tension element coupled to both the second handle arm and to the second jaw member, and a lock that locks relative movement between the first and second handle arms. Rotational movement of the first and second handle arms generates correlated rotational movement of the first and second jaw members.
Abstract: Aspects of the invention relates to systems and methods for detecting volume status, volume overload, dehydration, hemorrhage and real time assessment of resuscitation, as well as organ failure including but not limited cardiac, renal, and hepatic dysfunction, of a living subject using non-invasive vascular analysis (NIVA). In one embodiment, a non-invasive device, which includes at least one sensor, is used to acquire vascular signals from the living subject in real time. The vascular signals are sent to a controller, which processes the vascular signals to determine at least one hemodynamic parameter, such as the volume status of the living subject. In certain embodiments, the vascular signals are processed by a spectral fast Fourier transform (FFT) analysis to obtain the peripheral vascular signal frequency spectrum, and the volume status of the living subject may be determined by comparing amplitudes of the peaks of the peripheral vascular signal frequency spectrum.
Type:
Grant
Filed:
November 13, 2015
Date of Patent:
October 29, 2019
Assignee:
Vanderbilt University
Inventors:
Susan Eagle, Colleen Brophy, Kyle Hocking, Franz Baudenbacher, Richard Boyer
Abstract: Disclosed is a compound of formula (I): wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.
Type:
Application
Filed:
December 14, 2017
Publication date:
October 24, 2019
Applicants:
ONO PHARMACEUTICAL CO., LTD., Vanderbilt University
Inventors:
Craig W LINDSLEY, Joshua M. WIETING, Kevin M. MCGOWAN, Jerod S. DENTON, Kentaro YASHIRO, Haruto KURATA, Yoko SEKIOKA, Takahiro MORI, Yuzo IWAKI
Abstract: In one aspect, the invention relates to polymers, crosslinked polymers, functionalized polymers, nanoparticles, and functionalized nanoparticles and methods of making and using same. In one aspect, the invention relates to degradable polymers and degradable nanoparticles. In one aspect, the invention relates to methods of preparing degradable nanoparticles and, more specifically, methods of controlling particle size during the preparation of degradable nanoparticles. In one aspect, the degradable nanoparticles are useful for complexing, delivering, and releasing payloads, including pharmaceutically active payloads. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Type:
Grant
Filed:
August 21, 2017
Date of Patent:
October 15, 2019
Assignee:
Vanderbilt University
Inventors:
Eva M. Harth, David J. Calkins, Alice E. Van Der Ende
Abstract: The invention generally relates in part to methods of effecting weight loss and/or improving glucose tolerance in a patient in need thereof, comprising administering a MetAP2 inhibitor.
Type:
Grant
Filed:
April 11, 2017
Date of Patent:
September 10, 2019
Assignees:
Zafgen, Inc., Vanderbilt University
Inventors:
Thomas E. Hughes, James E. Vath, Alan D. Cherrington
Abstract: Provided are compositions for inhibiting a biological activity of an aldo-keto reductase family 1, member C3 (AKR1C3) polypeptide. In some embodiments, the compositions are indomethacin derivatives that are AKR1C3-specific inhibitors. Also provided are methods for producing disclosed indomethacin derivatives that substantially lack cyclooxygenase inhibitory activity but that have AKR1C3 inhibitory activity, methods for inhibiting AKR1C3 polypeptide biological activities, and methods for treating prostate tumors in subjects.
Type:
Grant
Filed:
February 19, 2018
Date of Patent:
September 3, 2019
Assignees:
Vanderbilt University, The Trustees of the University of Pennsylvania
Inventors:
Lawrence J. Marnett, Andy J. Liedtke, Trevor M. Penning, Adegoke O. Adeniji, Michael C. Byrns
Abstract: Described are negative allosteric modulators of metabotropic glutamate receptor 3 (mGlu3), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating depression, cognitive disorders, schizophrenia, Alzheimer's disease, or cancer in a subject.
Type:
Grant
Filed:
February 10, 2016
Date of Patent:
September 3, 2019
Assignee:
Vanderbilt University
Inventors:
P. Jeffrey Conn, Craig W. Lindsley, Kyle A. Emmitte, Julie L. Engers, Katrina A. Bollinger, Megan M. Breiner
Abstract: A mucosal impedance measuring apparatus detects and measures a condition of mucosa. The mucosal impedance measuring apparatus includes a catheter comprising a tube, impedance sensing electrodes on an exterior surface of the catheter, a balloon mounted on the tube in which the balloon is capable of inflation and deflation, and an impedance measuring system. The impedance measuring system is adapted to measure a pressure-regulated impedance measurement of the mucosa that is indicative of the condition of the mucosa when the balloon is inflated and the impedance sensing electrodes direct an electric current through mucosa while the balloon is pressed against the mucosa.
Type:
Application
Filed:
May 6, 2019
Publication date:
August 22, 2019
Applicants:
Diversatek Healthcare, Inc., Vanderbilt University
Inventors:
Jerry E. Mabary, Michael F. Vaezi, Thomas D. Stuebe
Abstract: The present disclosure is directed to antibodies binding to human respiratory syncytial virus F protein, including both neutralizing and non-neutralizing antibodies, and methods for use thereof.
Abstract: The present disclosure relates to the fields of proliferative disorders (for example, cancer) and disorders associated with excessive cell death (for example, neurodegenerative disorders).
Type:
Grant
Filed:
February 9, 2018
Date of Patent:
August 6, 2019
Assignee:
Vanderbilt University
Inventors:
Vsevolod V. Gurevich, Eugenia V. Gurevich, Xuanzhi Zhan
Abstract: Disclosed herein are thieno[3,2-e][1,2,4]triazolo[1,5-a]pyridin-6-amine, thieno[3,2-e][1,2,4]triazolo[4,3-a]pyridin-3-amine, and imidazo[1,2-a]thieno[3,2-e]pyridin-3-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.
Type:
Grant
Filed:
July 27, 2017
Date of Patent:
July 9, 2019
Assignee:
Vanderbilt University
Inventors:
Craig W. Lindsley, P. Jeffrey Conn, Darren W. Engers, Carrie K. Jones, Thomas M. Bridges, Changho Han, Andrew S. Felts
Abstract: The present invention relates to compositions and methods for preventing and reducing inflammation and preventing and treating diseases and disorders associated with inflammation. It has been shown that CRADD plays a pivotal role in maintaining the integrity of endothelial monolayers. The recombinant cell-penetrating CRADD protein (CP-CRADD)-based compositions and methods described herein provide for the development of a novel treatment for inflammatory vascular disorders including cardiovascular, cerebrovascular, respiratory, gastrointestinal, and renal systems.
Type:
Grant
Filed:
February 29, 2016
Date of Patent:
July 9, 2019
Assignee:
Vanderbilt University
Inventors:
Jack J. Hawiger, Ruth Ann Veach, Yan Liu, Huan Qiao, Lukasz S. Wylezinski
Abstract: Methods of detecting a sulfur-containing compound in a sample are described, for example using NMR-SABRE hyperpolarization of the sulfur-containing compounds in the sample. The methods can comprise, for example, contacting a sample comprising a sulfur-containing compound with parahydrogen and a catalyst to form a mixture. A spin order can be transferred from the parahydrogen to the sulfur-containing compound thereby hyperpolarizing the sulfur-containing compound during a temporary association of the parahydrogen, the sulfur-containing compound, and the catalyst. The methods can further comprise, for example, performing an NMR measurement on the mixture comprising the hyperpolarized sulfur-containing compound to detect the hyperpolarized sulfur-containing compound (e.g., from the hyperpolarized NMR signals. In some examples, the methods described herein can be used for detecting a sulfur-containing contaminant in a fuel.